Medicina · 2022 · 11 citations · 20 references
MedicineOncologyRadiation OncologyBreast OncologyBreast Radiation OncologyRadiation DosimetryBreast Cancer RadiotherapyHypofractionated Breast RadiotherapyRadiation TherapyRadiation ToxicityThree-dimensional Conformal RadiotherapyWhole-breast Irradiation3D-conformal RadiotherapyBreast Cancer FractionationHypofractionated Radiation TherapyHypofractionated Whole-breast IrradiationHypofractionation ToxicityLate Skin ToxicityModerate HypofractionationNormal Tissue Dosimetry
Background and Objectives: Reducing time of treatment during COVID-19 outbreaks has been recommended by the leading Radiation Oncology societies. Still minimizing radiation induced tissue toxicity is one of the most important issues in breast cancer patients. The study aimed to investigate compliance, clinical and dosimetry normal tissue toxicity, and cosmetic results between moderated and ultra-fractionated regimes for breast cancer patients during COVID-19 pandemic. Materials and Methods: This pilot prospective randomized study included 60 patients with early breast cancer after preserving surgery, 27 patients advocated to ultra-hypofractionated whole-breast three dimensional (3D) conformal radiotherapy of 26 Gy in 5 fractions over 1 week and 33 patients with moderate fractionated breast 3D conformal radiotherapy patients between March 2020 and July 2020, during the COVID pandemic outbreak. The compliance to treatment, dosimetric parameters, acute and late skin toxicity, subcutaneous tissue toxicity, cosmetic results and clinical follow up for 18 months for the two regimes were analyzed and compared. Results: When two regimes were compared 5 fraction group had significantly lower prevalence of newly infected cases of SARS-CoV-2 and thus delayed/interrupted treatment (p = 0.05), comparable grade 1 CTCAE v5, acute skin toxicity (p = 0.18), Grade 1 Radiation Morbidity Scoring Scheme (RESS) subcutaneous tissue toxicity (p = 0.18), Grade 1 RESS late skin toxicity (p = 0.88) and cosmetic results (p = 0.46). Dosimetric results reveled that patients in 5 fraction group received significantly lower median ipsilateral lung doses (p < 0.01) in addition to left breast cancer patients that received significantly lower median heart dose (p < 0.01) and median left anterior descending artery (LAD) dose (p < 0.01). Conclusion: Ultra-hypofractionated radiotherapy for breast cancer is comparable to moderate hypofractionation regimen regarding grade 1 acute skin toxicity, grade 1 subcutaneous tissue toxicity, late skin toxicity and cosmetic results. Application of ultra-hypofractionated radiotherapy with significantly lower radiation doses for lung and heart could be crucial in reducing the risk of acute/late pulmonary and heart radiation-induced toxicity.
20
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Sarah C. Darby, Marianne Ewertz, Paul McGale et al. · New England Journal of Medicine · 2013 · 4K citations · Full text
Medicine, Cardiology, Oncology +17
Joanne Haviland, John R. Owen, John Dewar et al. · The Lancet Oncology · 2013 · 1.5K citations · Full text
What does 'access to health care' mean?
Martin Gulliford, J Figueroa-Munoz, Myfanwy Morgan et al. · Journal of Health Services Research & Policy · 2002 · 1.1K citations
Adrian Murray Brunt, Joanne Haviland, Duncan Wheatley et al. · The Lancet · 2020 · 1.1K citations · Full text
Veerle A.B. van den Bogaard, Bastiaan D.P. Ta, A. van der Schaaf et al. · Journal of Clinical Oncology · 2017 · 503 citations · Full text